An overview and recent developments of the STRATOS Open Science panel

Sabine Hoffmann on behalf of the Open Science panel

28.08.2025

Overview

- What is open science and why do we need it?
- Synthetic data generation to make biomedical research publicly available while protecting confidentiality
- Guidance on how to deal with research degrees of freedom in the analysis of observational data

Why do we need open science?

What is open science and why do we need it?


What is open science?

What is open science?


"Umbrella term that reflects the idea that scientific knowledge of all kinds, where appropriate, should be openly accessible, transparent, rigorous, reproducible, replicable, accumulative and inclusive"





Original population





Original population sample Original study data analyze / analyze Reproduce Original results results











Why do we need open science in clinical research?

Why Most Published Research Findings Are False



Seriors that indiscense this problem and

Modeling the Framework for False **Pesitive Findings**

(I) To keep health as a unifying force, we must put resources into tackling health misinformation and disinformation




SOLEN KYRKENGODES O

public and clinical health believe. Health and health policy are shaped by the political ideology of governments. whether that means more money to invest in health systems or less regulation on health-harming products. Health can also cut across political lines because health is a universally shared value. Everyone wants their loved ones to be healthy, so framing societal issues as health issues can draw people from across the political spectrum to advocate for change and policies. The health community has had successes using this strategy with, for example, the climate crisis and gun violence. Framing climate

Health is political. This is what many practitioners of themselves apart from opponents through differentiating policies. Yet because health often affects questions of bodily and individual autonomic it is also vulnerable to weaponisation through the shaping of narratives.


> As such, health can be used to ignite topics that are emblematic of broader societal conversations on the role of government and the state. In her book, Doppelgonger A Trip into the Mirror World. Naomi Klein argues that this phenomenon is more potent now because of the rising numbers of people who feel left behind and abandoned from decades of free market economics that have prioritised profits over the wellbeing of individuals.

Replication crisis in psychology Open Science Collaboration (2015)



Preclinical research Freedman

al. (2015)



and Classics et al. (1)

4 / 22

STRATOS and open science

| | STRATOS members | Research community |
|-----------------|---|---|
| Open access | Ideally, STRATOS publications should be open access | Underline importance of open access publications |
| Reproducibility | STRATOS papers should be reproducible (reproducibility checks: RH, FS) | Guidance reproducibility for level 1 audience |
| | STRATOS papers should use open access data sets | Guidance data sharing while protecting confidentiality |
| Transparency | Write study protocols (e.g. simulation protocol) and ask for community feedback | Open science practices to improve neutrality simulation studies |
| Replicability | | Guidance dealing with uncertain choices for level 1 audience |

Chairs: Sabine Hoffmann and Daniela Dunkler (since July 2025) Members: Anne-Laure Boulesteix, Roman Hornung, Michael Kammer, Kim Luijken, Willi Sauerbrei, Fabian Scheipl, Pamela Shaw, Ewout Steyerberg

Synthetic data generation to make biomedical research publicly available while protecting confidentiality

Joint work with Sarah Friedrich-Welz, Julia Höpler, Jan Kapar and Marvin Wright



Motivation


- Increasing awareness that data sharing:
 - Improves transparency, credibility and reproducibility
 - Increases reuse potential of scientific studies
 - Makes evidence synthesis more efficient

Motivation


- Increasing awareness that data sharing:
 - Improves transparency, credibility and reproducibility
 - Increases reuse potential of scientific studies
 - Makes evidence synthesis more efficient
- ⇒ Journals and funders are increasingly incentivizing or even requiring data sharing practices

Motivation


- Increasing awareness that data sharing:
 - Improves transparency, credibility and reproducibility
 - Increases reuse potential of scientific studies
 - Makes evidence synthesis more efficient
- ⇒ Journals and funders are increasingly incentivizing or even requiring data sharing practices
- ⇒ Many researchers lack skills and knowledge to make their data publicly available while protecting confidentiality





| Name | Date of birth | Location | Height | Diagnosis | Prescription | Heart rate |
|------|---------------|----------|--------|-----------|--------------|------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |



| Id | Age | Location | Height | Diagnosis | Prescription | Heart rate |
|----|-----|----------|--------|-----------|--------------|------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |









• How to share biomedical research data?



- How to share biomedical research data?
- How to evaluate the shared data set in terms. of disclosure risk and utility?

Reduce information

| Id | Age | Location | Height | Diagnosis | Prescription | Heart rate |
|----|-----|----------|--------|-----------|--------------|------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Reduce information

| Id | Age | Location | Height | Diagnosis | Prescription | Heart rate |
|----|-----|----------|--------|-----------|--------------|------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

Dropping variables

Reduce information

| Id | Age | Location | Height | Diagnosis | Prescription | Heart rate |
|----|-------|----------|--------|-----------|--------------|------------|
| | 20-25 | | | | | |
| | 55-60 | | | | | |
| | 90-95 | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

- Dropping variables
- Categorizing continuous variables or aggregating categories

Reduce information

| Id | Age | Location | Height | Diagnosis | Prescription | Heart rate |
|----|-------|----------|------------|-----------|--------------|------------|
| | 20-25 | | | | | |
| | 55-60 | | | | | |
| | 90-95 | | > 2 meters | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

- Dropping variables
- Categorizing continuous variables or aggregating categories
- Censoring



Reduce information

- Dropping variables
- Categorizing continuous variables or aggregating categories
- Censoring

Data perturbation

- Data swapping
- Adding noise

Reduce information

- Dropping variables
- Categorizing continuous variables or aggregating categories
- Censoring

Data perturbation

- Data swapping
- Adding noise

Reduce information

Data perturbation

- Data swapping
- Adding noise

- Methods:
 - Parametric methods
 - Deep learning:
 - Autoencoders
 - Generative Adversarial Networks

Reduce information

Data perturbation

- Methods:
 - Parametric methods
 - Deep learning:
 - Autoencoders
 - Generative Adversarial Networks
 - Tree-based methods
 - Synthpop (Nowok et al., 2016)
 - Adversarial Random Forests (Watson et al., 2023)

Reduce information

Data perturbation

- Methods:
 - Parametric methods
 - Deep learning:
 - Autoencoders
 - Generative Adversarial Networks
 - Tree-based methods
 - Synthpop (Nowok et al., 2016)
 - Adversarial Random Forests (Watson et al., 2023)
 - Bayesian networks



Reduce information

Data perturbation

- Methods:
 - Parametric methods
 - Deep learning:
 - Autoencoders
 - Generative Adversarial Networks
 - Tree-based methods
 - Synthpop (Nowok et al., 2016)
 - Adversarial Random Forests (Watson et al., 2023)
 - Bayesian networks
- Full or partial synthesis



Evaluating the quality of synthetic data



Data utility

Illustration: Data utility





Illustration: Disclosure risk



Open questions


• Does sampling already provide some confidentiality?

Open questions


- Does sampling already provide some confidentiality?
- Challenges:
 - Logical constraints between variables
 - Missing data
 - Longitudinal data
 - High-dimensional data

Guidance on how to deal with research degrees of freedom in the analysis of observational data

Researcher degrees of freedom in observational studies



Consequences of selective reporting




Original study

Replication study 1

Replication study 2

Consequences of selective reporting




Original study

Replication study 1

Replication study 2

Dealing with researcher degrees of freedom



Hoffmann, S., F. Schönbrodt, R. Elsas, R. Wilson, U. Strasser, Boulesteix, A. L. (2021). The multiplicity of analysis strategies jeopardizes replicability: lessons learned across disciplines. Royal Society Open Science 8 201925

Dealing with analytical choices in the analysis of observational studies (level 1/2 audience)

 Raise awareness of dangers of result-dependent selective reporting of analysis strategies

Dealing with analytical choices in the analysis of observational studies (level 1/2 audience)


- Raise awareness of dangers of result-dependent selective reporting of analysis strategies
- Illustrate solutions to deal with these analytical choices, tailored to observational studies in biomedical research:
 - Pre-registration
 - Increasing statistical power
 - Multiverse analyses, vibration of effects etc.
 - Validation on independent test data
 - Account for analytical variability through Bayesian hierarchical approaches

Association between body composition and cardiovascular disease

Literature review papers published in 2024

Joint work with Heiko Becher, Anne-Laure Boulesteix, Daniela Dunkler, Simon Lemster and Carsten Oliver Schmidt

Association between body composition and cardiovascular disease



Joint work with Heiko Becher, Anne-Laure Boulesteix, Daniela Dunkler, Simon Lemster and Carsten Oliver Schmidt

Association between body composition and cardiovascular disease



Joint work with Heiko Becher, Anne-Laure Boulesteix, Daniela Dunkler, Simon Lemster and Carsten Oliver Schmidt

Literature review: Exposure and outcome definitions

Body composition

- · Waist circumference
- Waist-to-hip ratio
- Percent body fat
- · Relative fat mass
- · Visceral adiposity index
- Body shape index
- · Arm fat-to-lean mass ratio
- · Leg fat-to-lean mass ratio
- BMI
- · Weight-adjusted-waist index
- · Body roundness index
- · Chinese visceral adiposity index
- MRI measurement of abdominal subcutaneous adipose tissue

Cardiovascular disease

- Self-report of diagnosed cardiovascular disease or events
- Cardiovascular **mortality** (Death certificates)
- Hospitalisation for cardiovascular disease or events
- Prescription of medication, surgery or other procedures indicating cardiovascular disease
- Physical examination: pathological Q wave (ECG)
- Any combination of stroke/heart attack, coronary artery disease/angina/congestive heart failure/other heart problem/acute rheumatic fever/chronic rheumatic heart disease/arterial fibrillation or flutter

Literature review: Eligibility and confounders


 $Table \ \delta$. Overview of the most frequently used variable groups for eligibility exiteria

| Variable group | Category | n (%) |
|---------------------------------|---------------------------|------------|
| Age | demographic | 70 (82.4%) |
| Cardiovascular disease (CVD) | comorbidity | 55 (64.7%) |
| Cancer | comorbidity | 20 (23.5%) |
| Pregnancy | reproductive health | 12 (14.1%) |
| Body mass index (BMI) | body composition | 9 (10.6%) |
| Diabetes | comorbádity | 7 (8.2%) |
| Early death/short follow-up | comorbidity | 7 (8.2%) |
| Kidney disease | comorbidity | 6 (7.1%) |
| General cardiometabolic/chronic | comorbidity | 6 (7.1%) |
| disease | | |
| Waist circumference (WC) | body composition | 6 (7.1%) |
| Residence in region/community | study design related | 5 (5.9%) |
| Medicine history | general treatment history | 4 (4.7%) |

Table 5. Overview of the most frequently used adjustment variable categories

| Category | n (%) |
|---------------------------------|------------|
| Age* | 79 (92.9%) |
| Smoking* | 74 (87.1%) |
| Sex* | 70 (82.4%) |
| Alcohol consumption* | 62 (72.9%) |
| Blood pressure* | 60 (70.6%) |
| Glucose metabolism* | 59 (69.4%) |
| Blood lipids* | 58 (68.2%) |
| Education* | 51 (60.0%) |
| Physical activity* | 42 (49.4%) |
| Body mass index (BMI)* | 30 (35.3%) |
| Economic status* | 28 (32.9%) |
| Ethnicity | 27 (31.8%) |
| Kidney function* | 27 (31.8%) |
| Civil status* | 24 (28.2%) |
| Cardiovascular disease history* | 22 (25.9%) |
| Inflammatory markers* | 17 (20.0%) |
| Diet* | 16 (18.8%) |
| Residence/registration | 16 (18.8%) |
| Family history* | 13 (15.3%) |
| Cancer history* | 12 (14.1%) |

Results of $16 \times 2 \times 6 \times 2 \times 3 \times 470 = 541.440$ analyses



• Guidance on reproducibility (Kim Luijken, Michael Kammer, Roman Hornung, Boris Hejblum)

- Guidance on reproducibility (Kim Luijken, Michael Kammer, Roman Hornung, Boris Hejblum)
- Improving the neutrality of simulation studies through open science practices

- Guidance on reproducibility (Kim Luijken, Michael Kammer, Roman Hornung, Boris Hejblum)
- Improving the neutrality of simulation studies through open science practices
- Adding measurement error to generate synthetic data

- Guidance on reproducibility (Kim Luijken, Michael Kammer, Roman Hornung, Boris Hejblum)
- Improving the neutrality of simulation studies through open science practices
- Adding measurement error to generate synthetic data
- Internal guidance for STRATOS projects

Thank you for your attention!

- Freedman, L. P., Cockburn, I. M., and Simcoe, T. S. (2015). The economics of reproducibility in preclinical research. *PLoS Biol*, 13(6):e1002165.
- Nowok, B., Raab, G. M., and Dibben, C. (2016). synthpop: Bespoke Creation of Synthetic Data in R. *Journal of Statistical Software*, 74(11).
- Open Science Collaboration (2015). Estimating the reproducibility of psychological science. *Science*, 349(6251):aac4716.
- Watson, D. S., Blesch, K., Kapar, J., and Wright, M. N. (2023). Adversarial random forests for density estimation and generative modeling. In *International Conference on Artificial Intelligence and Statistics*, pages 5357–5375. PMLR.